Apomorphine's second act

A different lever: dopamine, not blood flow

Apomorphine is real pharmacology, and its mechanism is genuinely interesting. Despite the name, it's not an opioid. It's a dopamine agonist that acts in the brain, mainly on D2 receptors in the hypothalamus, at one of the switchboards where sexual arousal is assembled. Stimulate it and the brain sends a pro-erectile signal down the spinal cord.

That makes it a central lever, upstream of the erection, where a PDE5 inhibitor like sildenafil or tadalafil is peripheral hydraulics – it helps penile blood vessels open once arousal is already happening. Same upstream/downstream split we walked through for bremelanotide + PDE5, and on paper the combination logic is identical: two different levers on two different parts of the problem.

Act one: Uprima, tested and retired

Here's what makes apomorphine different from most gray-zone ingredients: it already had its fair trial. Sublingual apomorphine was developed as a real drug (Uprima, also sold as Ixense) and approved in Europe in 2001. In the pivotal studies, the 3 mg dose produced erections firm enough for intercourse in about 49% of attempts, against a baseline of about 24%. Real, measurable, and honest. Also clearly weaker than the PDE5 inhibitors it had to compete with.

Then came the tolerability bill. The signature side effect was nausea, the most common reason men quit the drug, with dizziness, yawning, and in rare cases fainting alongside. Public Citizen formally urged the FDA to reject it over the syncope cases, the US application was withdrawn, and after a few quiet years in Europe the product was discontinued there too.

The molecule kept its legitimate career where the mechanism fits: apomorphine remains an approved rescue therapy in Parkinson's disease, where its dopamine agonism is the whole point, and where nausea is so expected that pre-treating with an anti-nausea drug is standard discussion.

Act two: the compounded troche

Twenty years later apomorphine is back, and what changed isn't the science. It's the business model. Compounding pharmacies can legally combine patent-expired drugs into "personalized" formulations that never have to pass a clinical trial, and telehealth turned that into a national mail-order channel. The flagship products are sublingual troches that pair a full-strength sildenafil dose with a large tadalafil dose (formulas on the market run up to 100 mg and 40 mg respectively, the tadalafil several times a typical on-demand amount) plus about 6 mg of apomorphine. Sold as "3-in-1" and "3x stronger than generics," by one flagship brand and by compounding pharmacies supplying med spas and telehealth clinics with essentially the same recipe.

Two things are true at once. First: this specific three-drug combination has never been through a clinical trial, and apomorphine has never been FDA-approved for erectile dysfunction. Second: the products mostly do work for the men who take them, because a maximum dose of sildenafil stacked with a multiple of the usual tadalafil dose is a very large amount of PDE5 inhibition. Which raises the only question that matters: which ingredient are you paying for?

What users actually report

Read enough user feedback on the troches and a consistent picture forms, and it's the picture the pharmacology predicts:

None of this makes the troche dangerous by compounded-product standards, and a licensed 503A/503B pharmacy with a real prescription is the legitimate channel. The point is narrower: the evidence says you're buying a premium wrapper around two generics you could fill for a few dollars.

Meanwhile, the conversation moved to androgens

Here's the part the ads won't tell you. In the communities that log and compare these things over years, the men chasing better desire and erection quality (as distinct from acute rigidity, which PDE5 inhibitors own outright) largely didn't land on dopamine agonists. They landed on androgens: specifically DHT and its derivatives, with mesterolone (Proviron) the perennial name, used as an add-on by men already on testosterone therapy.

The mechanistic story is coherent: DHT binds the androgen receptor several-fold more strongly than testosterone, genital tissue is DHT-dominant, desire itself is androgen-dependent, and mesterolone also lowers SHBG, which raises the free fraction of testosterone. And the epistemics are almost a mirror image of the troche: apomorphine has trials proving modest efficacy and a marketing machine behind it; mesterolone has no modern trials and no marketing at all, and survives purely on decades of repeated first-person reports.

Now the fence, stated plainly. Those reports are Anecdote grade: consistent, but never run through the trials that would separate effect from expectation. Mesterolone is not FDA-approved, and in the US, DHT-derivative anabolics are Schedule III controlled substances, which means the supply is gray-market with all the identity and purity problems that implies, plus real androgen side effects (hair, lipids, prostate monitoring, suppression). We don't publish protocols for that, and the honest version of this signal isn't "source Proviron." It's that if desire and erection quality are the problem, your androgen status is the first thing worth checking with a clinician, with real labs, inside the legal channel.

The bottom line

Apomorphine is a real molecule with a fair trial on the books, and the verdict from that trial hasn't changed: modest efficacy, nausea as the price, retired for cause. The troche revival re-sells that molecule inside a large double dose of PDE5 generics, at a multiple of the generic price, with no new evidence, and user feedback keeps rediscovering the original verdict one queasy evening at a time. If a prescriber and a licensed pharmacy stand behind a troche and it works for you, that's a legitimate treatment. But know which ingredient is working, pay generic prices for it where you can, and take the desire-and-quality question where it actually leads: a real evaluation and your own lab work, not a stronger-sounding lozenge.

Common questions